Literature DB >> 25370368

Healthcare professional requirements for the care of adult diabetes patients managed with insulin pumps in Australia.

S Xu1, K Alexander, W Bryant, N Cohen, M E Craig, M Forbes, G Fulcher, T Greenaway, N Harrison, D J Holmes-Walker, G Howard, J Jackson, A Jenkins, M Kamp, J Kaye, A Sinha, S Stranks, D O'Neal, P Colman.   

Abstract

BACKGROUND: Healthcare professional (HCP) time supporting insulin pump therapy (IPT) has not been documented, yet it is important in planning and allocating resources for effective care. AIM: This study aims to determine HCP time spent in IPT patient care to inform resource planning for optimal IPT delivery.
METHODS: Twenty-four Australian adult IPT-experienced institutions (14 government funded, seven private, three both) collected data between April 2012 and January 2013 prospectively, including: patient demographics, HCP classification, purpose of HCP-patient interaction, interaction mode and HCP time with the patient. A subset of patients was tracked from pre-pump education until stable on IPT.
RESULTS: Data on 2577 HCP-adult patient interactions (62% face-to-face, 29% remote, 9% administrative) were collected over 12.2 ± 6.4 weeks for 895 patients; age 35.4 ± 14.2 years; 67% female; 99% type 1 diabetes, representing 25% of all IPT patients of the institutions. Time (hours) spent on IPT interactions per centre per week were: nurses 5.4 ± 2.8, dietitians 0.4 ± 0.2 and doctors 1.0 ± 0.5. IPT starts accounted for 48% of IPT interaction time. The percentage of available diabetes clinic time spent on outpatient IPT interactions was 20.4%, 4.6% and 2.7% for nurses, dietitians and doctors respectively. Fifteen patients tracked from pre-pump to stabilisation over 11.8 ± 4.5 weeks, required a median (range) of 9.2 (3.0-20.9), 2.4 (0.5-6.0) and 1.8 (0.5-5.4) hours per patient from nurses, dietitians and doctors respectively.
CONCLUSIONS: IPT patient care represents a substantial investment in HCP time, particularly for nurses. Funding models for IPT care need urgent review to ensure this now mainstream therapy integrates well into healthcare resources.
© 2014 Royal Australasian College of Physicians.

Entities:  

Keywords:  health resource; health service need and demand; insulin; insulin infusion system; type 1 diabetes mellitus

Mesh:

Substances:

Year:  2015        PMID: 25370368     DOI: 10.1111/imj.12619

Source DB:  PubMed          Journal:  Intern Med J        ISSN: 1444-0903            Impact factor:   2.048


  5 in total

1.  Development of an integrated, district-wide approach to pre-pregnancy management for women with pre-existing diabetes in a multi-ethnic population.

Authors:  Maryam Sina; Freya MacMillan; Tinashe Dune; Navodya Balasuriya; Nouran Khouri; Ngan Nguyen; Vasyngpong Jongvisal; Xiang Hui Lay; David Simmons
Journal:  BMC Pregnancy Childbirth       Date:  2018-10-15       Impact factor: 3.007

2.  Diabetes Educators: Perceived Experiences, Supports and Barriers to Use of Common Diabetes-Related Technologies.

Authors:  Steven James; Lin Perry; Robyn Gallagher; Julia Lowe
Journal:  J Diabetes Sci Technol       Date:  2016-08-22

3.  A Pilot Study of Use of a Software Platform for the Collection, Integration, and Visualization of Diabetes Device Data by Health Care Providers in a Multidisciplinary Pediatric Setting.

Authors:  Jenise C Wong; Zara Izadi; Shannon Schroeder; Marie Nader; Jennifer Min; Aaron B Neinstein; Saleh Adi
Journal:  Diabetes Technol Ther       Date:  2018-11-21       Impact factor: 6.118

4.  Impact of government-funded insulin pump programs on insulin pump use in Canada: a cross-sectional study using the National Diabetes Repository.

Authors:  Cimon Song; Gillian L Booth; Bruce A Perkins; Alanna Weisman
Journal:  BMJ Open Diabetes Res Care       Date:  2021-10

5.  HbA1c variability in adults with type 1 diabetes on continuous subcutaneous insulin infusion (CSII) therapy compared to multiple daily injection (MDI) treatment.

Authors:  Emma S Scott; Rachel T McGrath; Andrzej S Januszewski; Daniel Calandro; Anandwardhan A Hardikar; David N O'Neal; Gregory Fulcher; Alicia J Jenkins
Journal:  BMJ Open       Date:  2019-12-29       Impact factor: 2.692

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.